Skip to main content
. Author manuscript; available in PMC: 2015 Nov 24.
Published in final edited form as: J Pharm Drug Deliv Res. 2015 Mar 20;4(1):129. doi: 10.4172/2325-9604.1000129

Figure 5.

Figure 5

Relative cytotoxic anti-neoplastic potency of fludarabine- (C2-methylhydroxyphosphoramide) - [anti - IGF-1R] against chemotherapeutic-resistant pulmonary adenocarcinoma. Legends: (α) fludarabine-(C2-methylhydroxyphosphoramide)-[anti-IGF-1R]; and fludarabine chemotherapeutic. Formulated in triplicate at gradient standardized (fludarabine-equivalent) concentrations, both fludarabine- (C2-methylhydroxyphosphoramide)-[anti-IGF-1R] and fludarabine were separately incubated in direct contact with monolayer populations of chemotherapeutic-resistant pulmonary adenocarcinoma (A549) for a period of 192-hours. Cytotoxic anti-neoplastic potency was measured using a MTT cell vitality assay relative to matched negative reference controls.